<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **BL-1 and BL-E**  
External request  
Submission from Pacific Edge Diagnostics for BL-1: include the Cxbladder assays as a component of the Initial Evaluation. Specifically, below the bullet "Consider cytology", add a new bullet with "Consider Cxbladder. For BL-E: include the Cxbladder assays in the list corresponding to "Urine Tests - Consider urinary urothelial tumor markers". Specifically, on MS-10 Surveillance replace "Consideration may be given to FDA-approved urinary biomarker testing by fluorescence in situ hybridization (FISH) or nuclear matrix protein 22 in monitoring for recurrence" with "Consideration may be given to urinary biomarker testing by fluorescence in situ hybridization (FISH), nuclear matrix protein 22, or Cxbladder mRNA gene expression in monitoring for recurrence".  
• Based on discussion, the panel consensus was to not include "Cxbladder assays" due to its limited use and available data.  
  o See Submission for references. | YES | NO | ABSTAIN | ABSENT |
| 0 | 15 | 0 | 12 |

| **BL-4**  
Internal request  
Institutional review comment to consider to include intravesical therapy as an option for non-cystectomy candidates with cT2 disease treated with TURBT alone.  
Based on discussion, the panel consensus was to include "consider intravesical BCG" as an option for non-cystectomy candidates with cT2 disease treated with TURBT alone. In addition, for adjuvant treatment after no tumor, "if prior BCG, maintenance BCG" was added. | 15 | 0 | 0 | 12 |